Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review.

53 – 56 In two prospective, randomized, open-label trials, bromfenac 0.1% showed similar effects compared to betamethasone and combination therapy (bromfenac/betamethasone) on measures of aqueous flare and corneal thickness following cataract surgery 57 but cleared ocular inflammation (based on mean photon count) after cataract surgery more rapidly than dexamethasone 0.1% ( P =0.001) and demonstrated a nonsignificant trend toward faster resolution compared to fluorometholone 0.1%. 58 A prospective, randomized study found that bromfenac 0.09% BID, ketorolac 0.4% TID, and nepafenac 0.1% TID all reduced postoperative inflammation by laser flare photometry values following phacoemulsification, with nepafenac showing a significantly greater reduction compared with bromfenac, ketorolac, and a no-NSAID control at 4 weeks postsurgery ( P =0.032). 59 These findings highlight the effectiveness of bromfenac ophthalmic solution given BID or QD for treating ocular inflammation and pain following cataract surgery.

also in 5,406 other papers